Dosage; Oral, 600mg every 12 hours for 10-14 days (max. duration of treatment 28 days);
Child 1 week-12 years, 10mg/kg every 8 hours;
12-18 years, adult dose. By I.V infusion over 30-120 minutes, 600mg every 12 hours;
child [unlicensed] 1 week-12 years, 10mg/kg every 8 hours; 12-18 years, adult dose.
Linezolid Brands
| Brand Name | Manufacturer Name | Distributor | Drug Strength | Packaging | Formulation | Formulation Strength | Price |
|---|---|---|---|---|---|---|---|
| Arlin | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 400mg | 40 | Tablet | per tablet | KES 3,528.00 |
| Arlin | Beximco Pharma | Madawa Pharmaceuticals Ltd. | 600mg | 40 | Tablet | per tablet | KES 4,635.00 |
| Linospa | Cipla Ltd. | Surgipharm Ltd | 2mg | 300ml | Injection | per vial | KES 1,178.00 |
| Lizolid | Glenmark | Galaxy Pharmaceuticals Ltd | 600mg | 300ml | Injection | per vial | KES 1,500.00 |
| Lizolid | Glenmark | Galaxy Pharmaceuticals Ltd | 600mg | 12 | Tablet | per tablet | KES 4,677.00 |
| Lizomed | Aglowmed Pharmaceuticals Ltd. | AB Pharmaceuticals Ltd | 600mg | 20 | Tablet | per tablet | KES 3,575.00 |
| Lizomed | Aglowmed Pharmaceuticals Ltd. | AB Pharmaceuticals Ltd | 100mg | 30ml | Suspension | per 5ML | KES 190.00 |
| Zyvox | Pfizer Global Pharmaceuticals | Laborex Kenya Eurapharma Ltd | 600mg | 300ml | Injection | per vial | KES 14,886.23 |
| Linezolid more info | |
|---|---|
| Mode Of Action | binds to the ribosomal 50S subunit in domain V of the 23S rRNA |
| Drug Indication | Community acquired pneumonia; nosocomial pneumonia; complicated skin and skin structure infections; vancomycin resistant enterococci faecium; febrile neutr;openia septicaemia; endocarditis; osteomyelitis; surgical prophylaxis. |
| Precautions | Use of antibiotics may promote overgrowth of non-susceptible organisms. |
| Contra-Indications | Concurrent use with SSRIs, 5HT1 agonists, tricyclic antidepressants, sym-pathomimetics, dopaminergics, buspirone, pet-hidine and some opioid analgesics. Hypersensitivity to the drug or other product components. |
| Side Effects | Fever; dizziness; oral moniliasis; vaginal moniliasis; hypertension; dyspepsia; constipation; pruritus; insomnia; abdominal pain; tongue discolouration. |
| Dosage | By mouth, 600mg every 12 hours for 10-14 days (max. duration of treatment 28 days); child 1 week-12 years, 10mg/kg every 8 hours; 12-18 years, adult dose. By I.V infusion over 30-120 minutes, 600mg every 12 hours; child [unlicensed] 1 week-12 years, 10mg/kg every 8 hours; 12-18 years, adult dose. |
| Special Information | an Oxazolidinone |
| Pregnancy Category | Category C |
| Pregnancy Category Description | Drugs which, owing to their pharmacological effects, or may be suspected of causing detrimental effects on human foetus or neonates without causing malfunctions. These effects may be reversible |
| Drug Category | DRUGS ACTING ON INFECTIONS |
| Drug Sub-Category | Oxazolidinones |
Dosing: Adult
Usual dosage: Oral, I.V.: 600 mg every 12 hours
Indication-specific dosing:
VRE infections including concurrent bacteremia: Oral, I.V.: 600 mg every 12 hours for 14-28 days
MRSA infections:
Brain abscess, subdural empyema, spinal epidural abscess (unlabeled use; Liu, 2011): Oral, I.V.: 600 mg every 12 hours for 4-6 weeks
Meningitis (unlabeled use; Liu, 2011): Oral, I.V.: 600 mg every 12 hours for 2 weeks
Osteomyelitis (unlabeled use; Liu, 2011): Oral, I.V.: 600 mg every 12 hours for a minimum of 8 weeks (some experts combine with rifampin)
Pneumonia (healthcare associated or community acquired) (Liu, 2011): Oral, I.V.: 600 mg every 12 hours for 7-21 days
Septic arthritis (unlabeled use; Liu, 2011): Oral, I.V.: 600 mg every 12 hours for 3-4 weeks
Septic thrombosis of cavernous or dural venous sinus (unlabeled use; Liu, 2011): Oral, I.V.: 600 mg every 12 hours for 4-6 weeks
Nosocomial pneumonia, complicated skin and skin structure infections,
community-acquired pneumonia including concurrent bacteremia:
Oral, I.V.: 600 mg every 12 hours for 10-14 days.
Note: May consider 7-day treatment course (versus manufacturer recommended 10-14 days)
in patients with healthcare-, hospital-, and ventilator- associated pneumonia who have demonstrated good clinical response (ATS/IDSA, 2005).
Uncomplicated skin and skin structure infections: Oral: 400 mg every 12 hours for 10-14 days.
Note: 400 mg dose is recommended in the product labeling; however, 600 mg dose is commonly employed clinically (Stevens, 2005)
Dosing: Pediatric
(For additional information see "Linezolid: Pediatric drug information")
Usual dosage: Oral, I.V.:
Preterm neonates (<34 weeks gestational age): 10 mg/kg every 12 hours;
neonates with a suboptimal clinical response can be advanced to 10 mg/kg every 8 hours.
By day 7 of life, all neonates should receive 10 mg/kg every 8 hours.
Children ≤11 years: 10 mg/kg (maximum: 600 mg/dose) every 8 hours
Children ≥12 years: Refer to adult dosing.
Indication-specific dosing:
Nosocomial pneumonia, complicated skin and skin structure infections,
community acquired pneumonia including concurrent bacteremia: Oral, I.V.:
Preterm neonates (<34 weeks gestational age): 10 mg/kg every 12 hours;
neonates with a suboptimal clinical response can be advanced to 10 mg/kg every 8 hours.
By day 7 of life, all neonates should receive 10 mg/kg every 8 hours.
Infants (excluding preterm neonates <1 week) and Children ≤11 years: 10 mg/kg every 8 hours for 10-14 days
VRE infections including concurrent bacteremia: Oral, I.V.:
Preterm neonates (<34 weeks gestational age): 10 mg/kg every 12 hours;
neonates with a suboptimal clinical response can be advanced to 10 mg/kg every 8 hours.
By day 7 of life, all neonates should receive 10 mg/kg every 8 hours.
Infants (excluding preterm neonates <1 week) and Children ≤11 years: 10 mg/kg every 8 hours for 14-28 days
Children ≥12 years: Refer to adult dosing.
MRSA infections:
Brain abscess, subdural empyema, spinal epidural abscess (unlabeled use; Liu, 2011): Oral, I.V.:
Neonates: 10 mg/kg every 12 hours; neonates with a suboptimal clinical
response can advance to 10 mg/kg every 8 hours. By day 7 of life, all neonates should
receive 10 mg/kg every 8 hours. Total duration of therapy: 6 weeks
Children ≤ 11 years: 10 mg/kg every 8 hours for 4-6 weeks (maximum: 600 mg/dose)
Children ≥12 years: Refer to adult dosing.
Meningitis (unlabeled use; Liu, 2011): Oral, I.V.: Children ≥12 years: Refer to adult dosing.
Osteomyelitis (unlabeled use; Liu, 2011): Oral, I.V.:
Infants (excluding preterm neonates <1 week) and Children ≤11 years: 10 mg/kg
every 8 hours for a minimum of 4-6 weeks (maximum: 600 mg/dose)
Children ≥12 years: Refer to adult dosing.
Pneumonia (healthcare associated or community acquired) (Liu, 2011): Oral, I.V.:
Children ≤11 years: 10 mg/kg every 8 hours for 7-21 days (maximum: 600 mg/dose)
Children ≥12 years: Refer to adult dosing.
Septic arthritis (unlabeled use; Liu, 2011): Oral, I.V.:
Infants (excluding preterm neonates <1 week) and
Children ≤11 years: 10 mg/kg every 8 hours for 3-4 weeks (maximum: 600 mg/dose
Children ≥12 years: Refer to adult dosing.
Septic thrombosis of cavernous or dural venous sinus (unlabeled use; Liu, 2011): Oral, I.V.:
Children ≤11 years: 10 mg/kg every 8 hours for 4-6 weeks (maximum: 600 mg/dose)
Children ≥12 years and Adults: 600 mg every 12 hours for 4-6 weeks
Children ≥12 years: Refer to adult dosing.
Uncomplicated skin and skin structure infections: Oral:
Preterm neonates (<34 weeks gestational age): 10 mg/kg every 12 hours;
neonates with a suboptimal clinical response can be advanced to 10 mg/kg every 8 hours.
By day 7 of life, all neonates should receive 10 mg/kg every 8 hours.
Infants (excluding preterm neonates <1 week) and Children <5 years: 10 mg/kg every 8 hours for 10-14 days
Children 5-11 years: 10 mg/kg every 12 hours for 10-14 days
Children ≥12-18 years: 600 mg every 12 hours for 10-14 days
Dosing: Geriatric
Refer to adult dosing.
Dosing: Renal Impairment
No adjustment is recommended. The two primary metabolites may accumulate in
patients with renal impairment but the clinical significance is unknown.
Weigh the risk of accumulation of metabolites versus the benefit of therapy.
Monitor for hematopoietic (eg, anemia, leukopenia, thrombocytopenia) and neuropathic
(eg, peripheral neuropathy) adverse events when administering for extended periods.
Intermittent hemodialysis: Both linezolid and the two metabolites are eliminated by dialysis.
Linezolid should be given after hemodialysis.
Continuous renal replacement therapy (CRRT): No adjustment needed